Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2011
Principal Executive Offices: River Edge, New Jersey
This filing reports a specific corporate event under Item 8.01 (Other Events) and includes a press release as an exhibit.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a regulatory filing and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the submission of a regulatory application.
Guidance, Outlook, and Management Commentary
Regulatory Milestone: On August 11, 2011, Nephros, Inc. announced the filing of a 510(k) application with the U.S. Food and Drug Administration (FDA).
Subject: The application seeks clearance for the company's hemodiafiltration system.
Outlook: The filing indicates progress in the regulatory approval process for a key product but does not provide specific timelines for clearance or future financial guidance.
Investor Verification Checklist
- Verify the status of the 510(k) application for the hemodiafiltration system with the FDA.
- Review the attached press release (Exhibit 99.1) for detailed product specifications and strategic implications.
- Monitor subsequent filings for updates on FDA clearance decisions or clinical trial results.
- Check the company's most recent 10-Q or 10-K for current financial health, as this 8-K contains no financial data.